We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Seegene

  Gold Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants

By LabMedica International staff writers
Posted on 25 May 2021
Print article
Image: Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants (Photo courtesy of Seegene, Inc.)
Image: Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, Korea) has introduced a unique system for diagnosing COVID-19 variants at the European Congress of Clinical Microbiology (ECCMID) 2021.

Seegene's Dr. Guy Willem Lee, Director of Marketing Strategy introduced the diagnostic system at ECCMID 2021under the theme of "SARS-CoV-2 and Variants 'Full Screening' Solution" using its latest COVID-19 variant diagnostic tests. The 'Full Screening Solution' is a one-step system that can verify whether an individual has contracted coronavirus wildtype or the virus variant with a single real-time PCR test. Currently, health authorities are forced to go through an extra round of genomic sequencing to distinguish the existence of COVID-19 variants after standard PCR tests, automatically leading to a more prolonged testing time.

Against the backdrop of Seegene's 'Full Screening Solution' are the company's latest variant diagnostic tests, the Allplex SARS-CoV-2 Master Assay and Allplex SARS-CoV-2 Variants I Assay. The Allplex SARS-CoV-2 Master is an ideal way of screening for the COVID-19, as it provides results of whether a person is positive of the COVID-19 or even its variants. After an initial round of testing, Seegene's Allplex SARS-CoV-2 Variants I Assay will help identify multiple mutant variations in a single reaction.

The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes (E gene, RdRP gene, N gene and S gene) as well as five defined virus variants notably spotted in the most recognized lineages including B1.1.7, B.1.351, P.1 and B.1.1.207. Seegene's variant diagnostic test is the first such kind to simultaneously detect multiple coronavirus genes and differentiate virus variations, including those found to be more contagious and fatal. It is an ideal and economic way of screening coronavirus genes as the pandemic continues to rage with both the wildtype and its virus variants.

Lee proposed that the system would play a critical role in controlling the spread of COVID-19 pandemic amid fast spreading virus variants.

“The backdrop of Korea's outstanding control at the onset of the pandemic is because of the one-platform diagnostic system that enables mass testing," said Lee. He added that “the system enabled the diagnostic process from sample collection through PCR testing all at once, helping local authorities to quickly control the pandemic.”

"A swift diagnostic system is extremely critical in helping to control the resurgence of the COVID-19 pandemic," added Dr. Nakmoon Sung of Seegene Medical Foundation. "The one-step and accurate diagnostics will become the global standard in detecting coronavirus and other respiratory diseases, for the purpose of accurate treatment".


New
Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
COVID-19 Antigen Test
Instant-view PLUS COVID-19 Antigen Test
New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
Silver Supplier
Third Party Immunoassay QC
Multichem IA Plus

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.